EMA recommends marketing authorization for donanemab (Kisunla)
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
The 78th World Health Assembly agrees to extend the Global Action Plan on the Public Health Response to Dementia
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
People with dementia must be priority for COVID-19 vaccine access
People with dementia must be included in the priority groups for new COVID-19 vaccines, both in care homes and at home, say Alzheimer’s Disease International People with dementia are being disproportionately affected by COVID-19 and amongst most vulnerable in society Recent studies show COVID-19 deaths disproportionately affecting people with dementia;…
Open to all: British Land and Canada Water
Emma Cariaga and Ginny Warr of British Land explore what inclusive design means for older people and for business growth. They look at Canada Water, where British Land is creating London’s first new town centre in over 100 years, and at activities across the company’s wider portfolio.
‘Dementia, lessons learned from Qatar’ launched at WISH 2020 Qatar Summit
A new policy briefing, co-authored by ADI, thoroughly examines dementia care policy in Qatar.
New Alzheimer’s disease data platform launched
A new data platform AD Workbench was launched by the Alzheimer’s Disease Data Initiative (ADDI).
Souvenaid results offer hope for those with early Alzheimer’s disease, including Mild Cognitive Impairment
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
Evidence considered at FDA Advisory Committee for potential first new Alzheimer’s disease treatment in decades
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.
Welcome to our new website
We have a new website, with updated design and content. The site works better on mobile devices and brings together our resources, member information and programmes so they are easy to find.
Designing to support dignity and independence
Fiona Walsh writes about designing around the different challenges a person with dementia may experience – and how these design decisions can have a significant impact on a person’s dignity and independence